Related Experiment Videos
Analog of neuropeptide FF attenuates morphine abstinence syndrome
Abstract:
The octapeptide FLFQPQRFamide (neuropeptide FF or F8Fa) may play a role in opiate dependence and subsequent abstinence syndrome. Previously, NPFF precipitated opiate abstinence syndrome, while IgG from NPFF antiserum attenuated subsequent naloxone-precipitated abstinence signs in dependent rats. The peptide desamino YFLFQPQRamide (daY8Ra) was synthesized as a possible NPFF antagonist. At a dose of 600 ng ICV, daY8Ra significantly attenuated (p less than 0.001) the number of abstinence-like signs subsequently induced by 10 micrograms NPFF ICV, suggesting that daY8Ra does have antagonist activity against NPFF. Pretreatment of morphine-dependent rats with the same dose of daY8Ra also significantly attenuated (p less than 0.001) the abstinence signs subsequently precipitated by 10 micrograms naloxone ICV. Pretreatment with 600 ng of NPFF itself, or of NPFF modified at the N-terminal only (daY9Fa), failed to attenuate subsequent naloxone-precipitated abstinence, suggesting that the C-terminal modification is critical for NPFF antagonist activity. It should be noted, however, that higher doses of daY8Ra (2 micrograms or more) can precipitate some abstinence signs in a manner similar to NPFF.
Insights
The novel peptide desamino YFLFQPQRamide (daY8Ra) acts as an antagonist to neuropeptide FF (NPFF), reducing opiate withdrawal symptoms in rats. However, higher doses of daY8Ra can induce withdrawal signs.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Research
Background:
- Neuropeptide FF (NPFF) is implicated in opiate dependence and withdrawal.
- Previous studies showed NPFF precipitates opiate abstinence, while antibodies against it attenuate withdrawal signs.
Purpose of the Study:
- To investigate the potential of a synthesized peptide, desamino YFLFQPQRamide (daY8Ra), as an NPFF antagonist.
- To evaluate the efficacy of daY8Ra in attenuating opiate abstinence syndrome in a rat model.
Main Methods:
- Rats dependent on morphine were treated with daY8Ra before challenge with NPFF or naloxone.
- Abstinence-like signs were quantified to assess the effects of daY8Ra.
- Control experiments included NPFF and a modified NPFF (daY9Fa) to determine critical structural features for antagonism.
Main Results:
- A dose of 600 ng ICV of daY8Ra significantly attenuated NPFF-induced and naloxone-precipitated abstinence signs in morphine-dependent rats.
- NPFF and daY9Fa did not attenuate naloxone-precipitated abstinence, indicating the C-terminal modification is crucial for antagonist activity.
- Higher doses of daY8Ra (≥2 µg) could precipitate abstinence signs, similar to NPFF.
Conclusions:
- The synthesized peptide daY8Ra exhibits antagonist properties against neuropeptide FF (NPFF).
- daY8Ra effectively reduces opiate withdrawal symptoms, suggesting therapeutic potential.
- The C-terminal modification of NPFF is critical for its antagonist activity, but high doses of daY8Ra warrant caution due to potential agonist-like effects.